piroxicam displaces other drugs from communication with blood proteins. Piroxicam reduces the effectiveness of antihypertensive drugs. While taking corticosteroids and other non-steroidal anti-inflammatory drugs, the risk of ulcerogenic exposure to piroxicam increases. The risk of developing hyperkalemia increases with the combined use of piroxicam with potassium-containing drugs and potassium-sparing diuretics. Piroxicam increases the concentration of lithium and phenytoin in the blood. With the combined use of piroxicam and anticoagulants, the risk of bleeding increases. Acetylsalicylic acid reduces the content of piroxicam in the blood by 20%.
Release form
Hard gelatin capsules, size No. 3, with a white body and a blue cap; the contents of the capsule is a powder from white to a creamy white color, the formation of a cylindrical shape, which easily disintegrates when touched, is possible.
10 pieces. - blisters (2) - packs of cardboard. Hard gelatin capsules, size No. 3, with a cream body and an orange cap; the contents of the capsule is a powder from white to a creamy white color, the formation of a cylindrical shape, which easily disintegrates when touched, is possible.
Shell composition: gelatin, titanium dioxide, iron oxide yellow, sunset yellow. 10 pieces. - blisters (2) - packs of cardboard.
Overdose
Symptoms: in isolated cases, systemic side effects may occur (headache, nausea, epigastric pain, shortness of breath; one case of interstitial nephritis with functional renal failure and nephrotic syndrome has been described).
Treatment: the drug should be discontinued. Symptomatic therapy.
For oral administration, the dose is 10-30 mg 1 time per day. In acute conditions or an exacerbation of the chronic process, you can enter intramuscularly in a dose of 20-40 mg once a day. After stopping the acute process, they switch to maintenance therapy with oral forms. Topically applied 3-4 times a day.